The EPIC-Norfolk Study

 

Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.

Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, and Boekholdt SM

Arteriosclerosis, thrombosis, and vascular biology. Mar 2009

(DOI : 10.1161/ATVBAHA.109.184101)

---